US 12,234,276 B2
Uterine cancer treatments
Andrea Mahr, Tuebingen (DE); Toni Weinschenk, Aichwald (DE); Colette Song, Ostfildern (DE); Oliver Schoor, Tuebingen (DE); Jens Fritsche, Dusslingen (DE); and Harpreet Singh, Munich (DE)
Assigned to Immatics Biotechnologies Gmbh, Tübingen (DE)
Filed by Immatics Biotechnologies GmbH, Tuebingen (DE)
Filed on Jun. 11, 2021, as Appl. No. 17/345,553.
Application 17/345,553 is a continuation of application No. 16/680,634, filed on Nov. 12, 2019, granted, now 11,390,660.
Application 16/680,634 is a continuation of application No. 16/154,457, filed on Oct. 8, 2018, granted, now 10,669,325, issued on Jun. 2, 2020.
Application 16/154,457 is a continuation of application No. 15/451,167, filed on Mar. 6, 2017, granted, now 10,138,287, issued on Nov. 27, 2018.
Claims priority of provisional application 62/305,222, filed on Mar. 8, 2016.
Claims priority of application No. 1603987 (GB), filed on Mar. 8, 2016.
Prior Publication US 2021/0309715 A1, Oct. 7, 2021
Int. Cl. A61K 38/00 (2006.01); A61K 35/17 (2015.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); C07K 7/06 (2006.01); C07K 14/47 (2006.01); C07K 14/725 (2006.01); C07K 14/74 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01); C12N 15/115 (2010.01); C12Q 1/6881 (2018.01); G01N 33/574 (2006.01); A61K 35/12 (2015.01); C07K 7/00 (2006.01)
CPC C07K 14/70539 (2013.01) [A61K 35/17 (2013.01); A61K 38/1709 (2013.01); A61K 39/0011 (2013.01); A61K 39/4611 (2023.05); A61K 39/4644 (2023.05); C07K 7/06 (2013.01); C07K 14/4748 (2013.01); C07K 14/7051 (2013.01); C07K 16/2833 (2013.01); C12N 5/0636 (2013.01); C12N 15/115 (2013.01); C12Q 1/6881 (2013.01); G01N 33/57484 (2013.01); A61K 2035/124 (2013.01); A61K 38/00 (2013.01); C07K 7/00 (2013.01); C07K 2319/00 (2013.01); C07K 2319/70 (2013.01); C12N 2310/16 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/156 (2013.01); G01N 2333/70539 (2013.01)] 17 Claims
 
1. An isolated peptide consisting of the amino acid sequence ALAPSEGVQAA (SEQ ID NO: 12) in the form of a pharmaceutically acceptable salt, wherein said peptide is produced by solid phase peptide synthesis or produced by a yeast cell or bacterial cell expression system.